Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine

The Journal of Infectious Diseases
Manjusha GaglaniMark Thompson

Abstract

Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1)pdm09-containing vaccines. We enrolled healthcare personnel (HCP) in direct patient care during the autumn of 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination inhibition antibody (HI) assays on preseason, post-TIV, and end-of-season serum samples. We compared the proportion of HCPs with HI titer ≥ 40 against A(H1N1)pdm09 per receipt of prior-season MIIV, current-season TIV, both, or neither. At preseason (n = 1417), HI ≥ 40 was significantly higher among those who received MIIV (34%) vs those who did not (14%) (adjusted relative risk [ARR], 3.26; 95% confidence interval [CI], 2.72-3.81). At post-TIV (n = 865), HI ≥ 40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%) (ARR, 0.93 [95% CI, .84-.997]). At end-of-season (n = 1254), HI ≥ 40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV (ARR, 0.76 [95% CI, .65-.88]), 52% among those who received MIIV only, and 12% among those receiving...Continue Reading

References

Feb 1, 1979·The Journal of Infectious Diseases·B J FeeryE I Morrison
Feb 1, 1988·American Journal of Epidemiology·W A KeitelR B Couch
Jan 1, 1984·Journal of Medical Virology·R D PowersJ M Gwaltney
Mar 1, 1997·Journal of Health and Social Behavior·E L Idler, Y Benyamini
Dec 1, 1998·JAMA : the Journal of the American Medical Association·J Zhang, K F Yu
Mar 17, 1999·JAMA : the Journal of the American Medical Association·J A WildeM C Steinhoff
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·D J SmithA S Perelson
Aug 21, 2008·PloS One·Sanae SasakiHarry B Greenberg
Mar 10, 2009·Biologicals : Journal of the International Association of Biological Standardization·Jozef J P NautaAlbert D M E Osterhaus
Sep 12, 2009·The New England Journal of Medicine·Michael E GreenbergRussell L Basser
Sep 30, 2010·The Journal of Infectious Diseases·Kawsar R TalaatRuth A Karron
Oct 8, 2011·The Journal of Hospital Infection·A N M Ng, C K Y Lai

❮ Previous
Next ❯

Citations

Jan 20, 2017·Clinical and Vaccine Immunology : CVI·Puja Van EppsDavid H Canaday
Sep 12, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brendan FlanneryUNKNOWN US Flu VE Investigators
Jun 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara S KimManish Patel
Nov 8, 2018·BMC Infectious Diseases·Avital HirschUNKNOWN SHIRI workgroup
Apr 7, 2020·Influenza and Other Respiratory Viruses·Meredith G WesleyUNKNOWN VIP Cohort Study Working Group
Mar 3, 2015·Hospital Practice·Mazen S BaderJocelyn A Srigley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.